Previous reports have shown that the expression of miRNA was involved in the development or prognosis of Epstein-Barr virus associated gastric cancer (EBVaGC). Therefore, the expression or target genes of the EBV miRNA can be useful as biomarker for EBVaGC. This study investigated the clinical significance of EBV miRNA expressions in patients with EBVaGC.
After reviewing 1318 consecutive cases of surgically resected or endoscopic submucosal dissected gastric cancers, 120 patients were identified as EBV-positive using EBV-encoded RNA in-situ hybridization. Among the 120 patients, the miRNA expression was examined in 39 tumor and 39 paired normal mucosal tissues from available formalin-fixed paraffin embedded tissues. The ebv-miRNAs expression levels for ebv-miR-BART1-5p, ebv-miR-BART4-5p, and ebv-miR-BART20-5p were determined by quantitative real-time PCR and the data were normalized relative to U6 expression. The average value of ebv-miRNAs expression levels was used as the cutoff point.
The median age of the patients was 64 years (40-76) and 31 (79.5%) were male. The pathologic stages after surgical resection were as follows: stage I (n = 13), stage II (n = 12), and stage III (n = 14). The expression of these miRNAs was significantly higher in tumor tissue than paired normal tissue (P
The ebv-miR-BART1-5p, ebv-miR-BART4-5p, and ebv-miR-BART20-5p were highly expressed in EBVaGC tissues, and the expression level of ebv-miR-BART20-5p may predict RFS for patients with EBVaGC. Further studies are warranted to elucidate the roles of EBV miRNAs in carcinogenesis of EBVaGC, which would be a potential therapeutic target.
Clinical trial identification
Legal entity responsible for the study
Ministry of Health & Welfare, Korea
All authors have declared no conflicts of interest.